Pavlina Chrysafi

Dr. Pavlina Chrysafi

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Nikolaos PerakakisNikolaos Perakakis
Nikolaos Perakakis
PCPavlina Chrysafi
Pavlina Chrysafi
MFMichael Feigh
Michael Feigh
SVSanne Skovgard Veidal
Sanne Skovgard Veidal
CMChristos S. Mantzoros
Christos S. Mantzoros
Empagliflozin, an established treatment for type 2 diabetes (T2DM), has shown beneficial effects on liver steatosis and fibrosis in animals and in humans with T2DM, non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). However, little is known about the effects of empagliflozin on liver function in advanced NASH with liver fibrosis and without diabetes. This study aimed to assess the effects of empagliflozin on hepatic and metabolic outcomes in a diet-induced obese (DIO) and insulin-resistant but non-diabetic biopsy-confirmed mouse model of advanced NASH. Male C57BL/6JRj mice with a biopsy-confirmed steatosis and fibrosis on AMLN diet (high fat, fructose and cholesterol) for 36-weeks were randomized to receive for 12 weeks: (a) Empagliflozin (10 mg/kg/d p.o.), or (b) vehicle. Metabolic outcomes, liver pathology, markers of Kupffer and stellate cell activation and lipidomics were assessed at the treatment completion. Empagliflozin did not affect the body weight, body composition or insulin sensitivity (assessed by intraperitoneal insulin tolerance test), but significantly improved glucose homeostasis as assessed by oral glucose tolerance test in DIO-NASH mice. Empagliflozin improved modestly the NAFLD activity score compared with the vehicle, mainly by improving inflammation and without affecting steatosis, the fibrosis stage and markers of Kupffer and stellate cell activation. Empagliflozin reduced the hepatic concentrations of pro-inflammatory lactosylceramides and increased the concentrations of anti-inflammatory polyunsaturated triglycerides. Empagliflozin exerts beneficial metabolic and hepatic (mainly anti-inflammatory) effects in non-diabetic DIO-NASH mice and thus may be effective against NASH even in non-diabetic conditions.

1 July 2017 in Journal of Surgical Education
Verified
Journal Article
Closed access
PCPavlina Chrysafi
Pavlina Chrysafi
ESEffie Simou
Effie Simou
MMMarinos Makris
Marinos Makris
GMGeorge Malietzis
George Malietzis
GMGregory C. Makris
Gregory C. Makris

8 August 2024 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PCPavlina Chrysafi
Pavlina Chrysafi
KBKevin Barnum
Kevin Barnum
GGGenevieve M. Gerhard
Genevieve M. Gerhard
TCThita Chiasakul
Thita Chiasakul
ANArshit Narang
Arshit Narang
RPRushad Patell
Rushad Patell

8 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
PCPavlina Chrysafi
Pavlina Chrysafi
CJChinmay T. Jani
Chinmay T. Jani
MLMargaret Lotz
Margaret Lotz
OOOmar Al Omari
Omar Al Omari
HSHarpreet Singh
Harpreet Singh
PLPrudence Lam
Prudence Lam
Hereditary Breast and Ovarian Cancer (HBOC) and Lynch Syndrome (LS) are the most common inherited cancer syndromes identified with genetic testing. Testing, though, commonly reveals variants of uncertain significance (VUSs). This is a retrospective observational study designed to determine the prevalence of pathogenic mutations and VUSs in patients tested for HBOC and/or LS and to explore the characteristics of the VUS population. Patients 18–80 years old that met NCCN criteria for HBOC and/or LS genetic screening were tested between 2006 and 2020 at Mount Auburn Hospital in Cambridge, Massachusetts. A total of 663 patients were included in the study, with a mean age of 50 years old and 90% being females. Pathogenic mutations were identified in 12.5% and VUSs in 28.3%. VUS prevalence was associated with race (p-value = 0.019), being particularly higher in Asian populations. Patients with a personal history of breast cancer or family history of breast or ovarian cancer were more likely to have a VUS (personal breast: OR: 1.55; CI: 1.08–2.25; family breast: OR: 1.68; CI: 1.08–2.60, family ovarian OR: 2.29; CI: 1.04–5.45). In conclusion, VUSs appear to be detected in almost one third patients tested for cancer genetic syndromes, and thus future work is warranted to determine their significance in cancer development.

16 July 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PCPavlina Chrysafi
Pavlina Chrysafi
ADAndriy Derkach
Andriy Derkach
VXVasiliki Xirou
Vasiliki Xirou
MFMaly Fenelus
Maly Fenelus
RPRushad Patell
Rushad Patell
ALAvi Leader
Avi Leader

19 November 2026 in Blood Advances
Verified
Journal Article
Closed access
DTDouglas Tremblay
Douglas Tremblay
AKAmica Ko
Amica Ko
PCPavlina Chrysafi
Pavlina Chrysafi
JHJoan How
Joan How
RZRebecca Zon
Rebecca Zon
MLMandy N. Lauw
Mandy N. Lauw
Patients with myeloproliferative neoplasms (MPN) are at risk of splanchnic vein thrombosis (SVT). Previous studies have failed to demonstrate a benefit of hydroxyurea therapy in preventing recurrent thrombosis after SVT, but they are limited by small sample sizes and inability to account for starting, stopping, or switching of cytoreductive therapies. To better assess the impact of cytoreductive therapy on thrombosis recurrence, we performed a retrospective cohort study of patients with MPN-SVT from the international GASTRO-MPN consortium, treating cytoreductive therapy as a time-dependent covariate. We identified 757 patients, of whom 43% were treated with cytoreductive therapy. During a median follow-up of 7.4 years, 256 patients (34%) had thrombosis recurrence; 145 (19%) had SVT extension/recurrence/transjugular intrahepatic portosystemic shunt thrombosis, and 138 (18%) had a thrombosis recurrence outside the splanchnic bed (74% were venous). In addition, 262 patients (35%) experienced clinically relevant bleeding and 170 (22%) died. After adjusting for age, sex, previous thrombosis, timing of MPN diagnosis relative to SVT, anticoagulation initiation within 30 days of SVT diagnosis, MPN type, JAK2 status, other cancers and cirrhosis, cytoreductive therapy was associated with a decreased risk of recurrent thrombosis (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.50-0.89; P = .01). This was driven by a lower risk of SVT extension/recurrence (HR, 0.62; 95% CI, 0.42-0.90; P = .01) but not by extra-splanchnic thrombosis recurrence (HR, 0.97; 95% CI, 0.72-1.30; P = .82). In a subgroup of patients without erythrocytosis/thrombocytosis at initial SVT (n = 275), cytoreductive therapy was associated with an HR of 0.65 (95% CI, 0.40-1.07; P = .09) for recurrent thrombosis. These data support the use of cytoreductive therapy for patients with MPN-SVT to prevent recurrent thrombosis, particularly SVT extension/recurrence.